ALK, ALK receptor tyrosine kinase, 238

N. diseases: 519; N. variants: 41
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C1527390
Disease: Neoplasms, Intracranial
Neoplasms, Intracranial
0.320 GeneticVariation group BEFREE Key Messages: Next-generation ALK-TKIs are now replacing crizotinib as first-line treatment in ALKi-naïve ALK rearrangement NSCLC patients with brain metastasis, and they alone might have a strong efficacy against intracranial tumors in crizotinib-refractory situations in which occasion radiotherapy might be omitted. 31527380 2019
CUI: C1527390
Disease: Neoplasms, Intracranial
Neoplasms, Intracranial
0.320 Biomarker group BEFREE Here, we examined the efficacy of a selective ALK inhibitor alectinib/CH5424802 in preclinical models of intracranial tumors. 25205428 2014
CUI: C1527390
Disease: Neoplasms, Intracranial
Neoplasms, Intracranial
0.320 Biomarker group CTD_human Isolated central nervous system progression on Crizotinib: an Achilles heel of non-small cell lung cancer with EML4-ALK translocation? 22986231 2012